
Spectrum Pharmaceuticals SPPI
Quartalsbericht 2023-Q1
hinzugefügt 11.05.2023
Spectrum Pharmaceuticals Langfristiger Schuldenstrom 2011-2026 | SPPI
Langfristiger Schuldenstrom Jährlich Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 761 K | 1.28 M | 1.54 M | 1.68 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.68 M | 761 K | 1.32 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
194 M | $ 209.63 | -0.71 % | $ 371 B | ||
|
Verastem
VSTM
|
535 K | $ 4.99 | -5.77 % | $ 346 M | ||
|
VistaGen Therapeutics
VTGN
|
561 K | $ 0.57 | -5.85 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Voyager Therapeutics
VYGR
|
7.84 M | $ 3.96 | -4.24 % | $ 232 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 12.36 | -11.46 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
8.36 M | $ 6.39 | 3.06 % | $ 1.08 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Xenon Pharmaceuticals
XENE
|
1.37 M | $ 54.44 | -1.96 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
6.23 M | $ 5.41 | -2.87 % | $ 868 M | ||
|
X4 Pharmaceuticals
XFOR
|
994 K | $ 4.07 | -5.57 % | $ 172 M | ||
|
Xencor
XNCR
|
3.26 M | $ 11.4 | -7.43 % | $ 846 M | ||
|
XOMA Corporation
XOMA
|
2.46 M | $ 29.93 | -1.97 % | $ 362 M | ||
|
22nd Century Group
XXII
|
168 K | $ 2.41 | -18.03 % | $ 444 K | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M |